Market capitalization | DKK15.17b |
Enterprise Value | DKK13.41b |
P/E (TTM) P/E ratio | 13.28 |
EV/FCF (TTM) EV/FCF | 8.39 |
EV/Sales (TTM) EV/Sales | 2.21 |
P/S ratio (TTM) P/S ratio | 2.50 |
P/B ratio (TTM) P/B ratio | 1.42 |
Revenue growth (TTM) Revenue growth | 3.03% |
Revenue (TTM) Revenue | DKK6.08b |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
5 Analysts have issued a Bavarian Nordic forecast:
5 Analysts have issued a Bavarian Nordic forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6,077 6,077 |
3%
3%
|
|
Gross Profit | 3,186 3,186 |
19%
19%
|
|
EBITDA | 1,762 1,762 |
35%
35%
|
EBIT (Operating Income) EBIT | 1,150 1,150 |
45%
45%
|
Net Profit | 1,119 1,119 |
55%
55%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Head office | Denmark |
CEO | Paul Chaplin |
Employees | 1,379 |
Founded | 1992 |
Website | www.bavarian-nordic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.